Filtered By:
Drug: Cilostazol
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 208 results found since Jan 2013.
Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications
This article is protected by copyright. All rights reserved.PMID:34671983 | DOI:10.1002/jcph.1988
Source: The Journal of Clinical Pharmacology - October 21, 2021 Category: Drugs & Pharmacology Authors: Antonis A Manolis Theodora A Manolis Helen Melita Dimitri P Mikhailidis Antonis S Manolis Source Type: research
Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications
This article is protected by copyright. All rights reserved.PMID:34671983 | DOI:10.1002/jcph.1988
Source: The Journal of Clinical Pharmacology - October 21, 2021 Category: Drugs & Pharmacology Authors: Antonis A Manolis Theodora A Manolis Helen Melita Dimitri P Mikhailidis Antonis S Manolis Source Type: research
Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications
This article is protected by copyright. All rights reserved.PMID:34671983 | DOI:10.1002/jcph.1988
Source: The Journal of Clinical Pharmacology - October 21, 2021 Category: Drugs & Pharmacology Authors: Antonis A Manolis Theodora A Manolis Helen Melita Dimitri P Mikhailidis Antonis S Manolis Source Type: research
Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications
This article is protected by copyright. All rights reserved.PMID:34671983 | DOI:10.1002/jcph.1988
Source: The Journal of Clinical Pharmacology - October 21, 2021 Category: Drugs & Pharmacology Authors: Antonis A Manolis Theodora A Manolis Helen Melita Dimitri P Mikhailidis Antonis S Manolis Source Type: research
Current status of drug repositioning in hematology
Expert Rev Hematol. 2021 Oct 16. doi: 10.1080/17474086.2021.1995348. Online ahead of print.ABSTRACTINTRODUCTION: Drug repositioning (DR) is defined as determining new therapeutic applications for existing drugs. This approach is advantageous over de novo drug discovery in accelerating clinical development, in terms of lower costs, a shortened development period, a well-known action mechanism, a feasible dosage, and an acceptable safety profile.AREAS COVERED: This work was aimed at reviewing agents with successful DR in hematology.EXPERT OPINION: Thalidomide and plerixafor have been successfully repositioned for treating mu...
Source: Expert Review of Hematology - October 18, 2021 Category: Hematology Authors: Akihiro Ohmoto Shigeo Fuji Source Type: research
A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease
In conclusion, these results suggest cilostazol may have beneficial effects in patients with CAD or at a high risk of CV disease.PMID:35743723 | DOI:10.3390/jpm12060938
Source: Atherosclerosis - June 24, 2022 Category: Cardiology Authors: Jia-Ling Lin Wei-Kung Tseng Po-Tseng Lee Cheng-Han Lee Shih-Ya Tseng Po-Wei Chen Hsien-Yuan Chang Ting-Hsing Chao Source Type: research
